Biomarkers and Mass Spectrometry – Based Assays in Type 1 Diabetes Clinical Research

Event Details

Meeting Purpose

The precise and accurate quantification of proteins and peptides that are involved in diabetes pathogenesis will help facilitate research into disease mechanisms and ultimately improve the diagnosis, prognosis, and therapeutic management of patients with diabetes. NIDDK recently funded several projects that aim to use targeted mass spectrometry to quantify human plasma/serum proteins and peptides of interest to the obesity and diabetes clinical research community. During this symposium, members of the Targeted Mass spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium will provide an overview of the recent advances toward this goal, with a special focus on type 1 diabetes. Other speakers will highlight the importance of biomarkers and their harmonization in the study of diabetes and the care of patients with this important chronic disease.

Meeting Objectives

During this symposium, members of the Targeted Mass spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium will provide an overview of the recent advances toward this goal, with a special focus on type 1 diabetes. Other speakers will highlight the importance of biomarkers and their harmonization in the study of diabetes and the care of patients with this important chronic disease.

Registration Deadline

April 4, 2025

Agenda

7:30 a.m. – 8:00 a.m.

Light Breakfast

8:00 a.m. – 8:10 a.m.

History and Purpose of Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)
Salvatore Sechi, Ph.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)

8:10 a.m. – 8:20 a.m.

Welcome and Introduction
William Cefalu, M.D., Director, Division of Diabetes, Endocrinology, & Metabolic Diseases, NIDDK, NIH

8:20 a.m. – 9:00 a.m.

An Overview of Islet Autoantibody Testing Methods
Marian Rewers, M.D., Ph.D., University of Colorado Anschutz Medical Campus

9:00 a.m. – 9:25 a.m.

Plasma Proteomics for the Assessment of Patient Response to Therapy
Michael MacCoss, Ph.D., University of Washington

9:25 a.m. – 9:50 a.m.

Mass Spectrometry-based Discovery of Prohormone Processing Products as Potential Novel Biomarkers
Lorenz Nierves, Ph.D., PNNL

9:50 a.m. – 10:00 a.m.

Coffee Break

10:00 a.m. – 10:35 a.m.

Standardization of C-peptide/Insulin
Kuanysh Kabytaev, Ph.D., University of Missouri School of Medicine

10:35 a.m. – 11:00 a.m.

A Multiplex Assay for Proinsulin Proteoforms: Assay Development and Optimization
Jun Qu, Ph.D., University of Buffalo

11:00 a.m. – 11:25 a.m.

Progress Toward Novel Assays for Alternative Proglucagon Fragments
Katrina Forrest, University of Washington

11:25 a.m. – 12:00 p.m.

Biomarkers in Clinical Diabetes Research
Carmella Evans-Molina, M.D., Ph.D., Indiana University School of Medicine

12:00 p.m. – 12:45 p.m.

Lunch

12:45 p.m. – 1:10 p.m.

Exploratory Assessment of Proinsulin Proteoforms as Biomarkers of Beta Cell Stress in T1D
Weijun Qian, PNNL

1:10 p.m. – 1:35 p.m.

Quantification of Proinsulin in Human Plasma
Andy Hoofnagle, M.D., Ph.D., University of Washington

1:35 p.m. – 2:10 p.m.

A Clinical Lab Perspective of a Successful Biomarker
Robert Fitzgerald, Ph.D., University of California, San Diego

2:10 p.m. – 2:25 p.m.

Coffee Break

2:25 p.m. – 2:50 p.m.

Assessments of Novel Methods for Biomarker Discovery
Weijun Qian, Ph.D., PNNL
Jun Qu, Ph.D., University of Buffalo

2:50 p.m. – 3:15 p.m.

Interlaboratory Transfer of a Novel Assay for Glucagon and Oxyntomodulin
Jessica Becker, M.S., University of Washington

3:15 p.m. – 3:55 p.m.

Islet Prohormone Processing: pro|APP Forms as Novel Beta Cell Biomarkers in Diabetes
Bruce Verchere, Ph.D., University of British Columbia

4:00 p.m. – 5:00 p.m.

External Panel/Investigators Meeting

5:00 p.m.

Meeting Adjournment